Previous 10 | Next 10 |
2024-04-30 04:49:23 ET Summary On Monday, April 29, Annovis Bio announced their phase 2/3 Alzheimer's Disease trial results, causing stock to drop ~60%. Of the five pre-specified efficacy endpoints, only ADAS-Cog11 results were reported in some details, and only from ~28% of the c...
A look at the top 10 most actives in the United States Tesla Inc. (TSLA) rose 15.3% to $194.05 on volume of 241,483,966 shares SiNtx Technologies Inc. (SINT) rose 34.9% to $0.0545 on volume of 171,893,463 shares Collective Audience Inc. (CAUD) rose 61.6% to $0.6301 on volume of 156,906,40...
2024-04-29 11:17:50 ET Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects Annovis to release efficacy data on Alzheimer's drug in April Annovis Bio falls after Brookline Capital downgrades on PD trial complications Seeking Alpha...
Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD Improvement in cognition measured by ADAS-Cog 11 at three months is 3.3 points as compared to 0.3 for placebo, consistent with our previous Phase II AD/P...
2024-04-28 07:22:26 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: Wall Street Breakfast: The Week Ahead
2024-04-27 09:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...
2024-04-26 15:00:06 ET More on the markets SPY: The 'Value' From Equities Is Historically Low SPY: The Setup Looks Extremely Bearish Be Greedy When Others Are Fearful, Even If They Are Fearful For A Good Reason BofA watched clients retract $2B last week as th...
2024-04-02 12:53:01 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Annovis Bio (NYSE: ANVS ) just reported results for the fourth quarter of 2023. Annovis Bio reported earnings per share of -$2.33. This was below the analyst estimate for ...
2024-04-02 07:37:07 ET More on Annovis Bio Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects Annovis And Alzheimer's Disease: The Best-Laid Plans Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO Annovis...
MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fo...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...
Annovis Bio (NYSE: ANVS) , a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new data from its phase 3 PD s...
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a very pronounced improvement. Buntanetap showed statistical improvement in the ...